Short Reads


Apparently smoothing over past problems and threats of a lawsuit, Paradigm Genetics announced that former president and CEO John Ryals has left the company’s board of directors.


GPC Biotech fills up its clinical development stable in Princeton, NJ: Edward McNiff is VP of pharmaceutical development; Thomas McKearn is VP of medical affairs; Michael Petrone is VP of clinical operations; and John Slayback is director of analytical and formulation development and outsourcing.


Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.